» Articles » PMID: 22029654

Derivation and Feeder-free Propagation of Human Embryonic Stem Cells Under Xeno-free Conditions

Overview
Journal Cytotherapy
Publisher Elsevier
Date 2011 Oct 28
PMID 22029654
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Background Aims: Human embryonic stem (hES) cells hold great potential for cell therapy and regenerative medicine because of their pluripotency and capacity for self-renewal. The conditions used to derive and culture hES cells vary between and within laboratories depending on the desired use of the cells. Until recently, stem cell culture has been carried out using feeder cells, and culture media, that contain animal products. Recent advances in technology have opened up the possibility of both xeno-free and feeder-free culture of stem cells, essential conditions for the use of stem cells for clinical purposes. To date, however, there has been limited success in achieving this aim.

Methods, Results And Conclusions: Protocols were developed for the successful derivation of two normal and three specific mutation-carrying (SMC) (Huntington's disease and myotonic dystrophy 1) genomically stable hES cell lines, and their adaptation to feeder-free culture, all under xeno-free conditions.

Citing Articles

Efficient derivation and banking of clinical-grade human embryonic stem cell lines in accordance with Japanese regulations.

Takada K, Nakatani R, Moribe E, Yamazaki-Fujigaki S, Fujii M, Furuta M Regen Ther. 2022; 21:553-559.

PMID: 36397823 PMC: 9647332. DOI: 10.1016/j.reth.2022.10.006.


Epidermal Basement Membrane Substitutes for Bioengineering of Human Epidermal Equivalents.

Kolundzic N, Khurana P, Crumrine D, Celli A, Mauro T, Ilic D JID Innov. 2022; 2(2):100083.

PMID: 35199088 PMC: 8844655. DOI: 10.1016/j.xjidi.2021.100083.


Assessing BRCA1 activity in DNA damage repair using human induced pluripotent stem cells as an approach to assist classification of BRCA1 variants of uncertain significance.

Ozgencil M, Barwell J, Tischkowitz M, Izatt L, Kesterton I, Simpson M PLoS One. 2021; 16(12):e0260852.

PMID: 34855882 PMC: 8638976. DOI: 10.1371/journal.pone.0260852.


Cell-Based Therapy Manufacturing in Stirred Suspension Bioreactor: Thoughts for cGMP Compliance.

Nath S, Harper L, Rancourt D Front Bioeng Biotechnol. 2020; 8:599674.

PMID: 33324625 PMC: 7726241. DOI: 10.3389/fbioe.2020.599674.


Validation of Current Good Manufacturing Practice Compliant Human Pluripotent Stem Cell-Derived Hepatocytes for Cell-Based Therapy.

Blackford S, Ng S, Segal J, King A, Austin A, Kent D Stem Cells Transl Med. 2018; 8(2):124-137.

PMID: 30456803 PMC: 6344902. DOI: 10.1002/sctm.18-0084.